氨柔比星对治疗一线含铂化疗后复发患者的意义:一项多中心Ⅱ期临床研究的结果
被引量：1
Phase Ⅱ Study of Amrubicin as Second-Line Therapy in Patients with Platinum-Refractory Small-Cell Lung Cancer
摘要
3背景
小细胞肺癌占肺癌的15％，在确诊的时候已有60％～70％处于广泛期。尽管小细胞肺癌初治患者对化疗药物较敏感，但很快产生耐药性并复发，且复发患者的预后很差。
出处
《循证医学》
CSCD
2012年第1期38-40,共3页
The Journal of Evidence-Based Medicine
关键词
小细胞肺癌
复发
氨柔比星
small-cell lung cancer
refractory
Amrubicin
参考文献4
-
1Jotte R, Conkling P, Reynolds C, et al. Randomized phase I1 trial of single-agent Amrubicin or Topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011, 29 ( 3 ) : 287-293.
-
2Schmittel A. Second-line therapy for small-cell lung cancer [ J ]. Expert Rev Anticancer Ther, 2011,11 (4) : 631-637.
-
3Nogami N, Hotta K, Kuyama S, et al. A phase 11 study of Amrubicin and Topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama lung cancer study group trial 0401[J]. Lung Cancer, 2011,74 (1) :80-84.
-
4Zatlouka| P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase m study comparing Cisplatin in combination with Irinotecan or Etoposide in previously untreated small-cell lung cancer patients with extensive disease [J]. Ann Oncol, 2010, 21(9): 1810-1816.
同被引文献18
-
1曹子昂.2014第一版NCCN小细胞肺癌治疗指南解读[J].中国医学前沿杂志（电子版）,2013,5(12):79-81. 被引量：26
-
2陈东福,吕纪马,周宗枚,王绿化,张宏兴,冯勤富,梁军,肖泽芬,张世平,张香茹,殷蔚伯.放射治疗在广泛期小细胞肺癌治疗中的影响[J].医学研究杂志,2006,35(4):15-17. 被引量：16
-
3Ding Q, Zhan J.Amrubicin:potential in combination with cisplatin or carboplatin to treat small-cell lung cancer[J]. Drug Des Devel Ther, 2013(7):681-689.
-
4Sgambato A, Casaluce F, Maione P, et al. Medical treatment of small cell lung cancer: state of the art and new development[J]. Expert Opin Pharmacother, 2013, 14(15):2019-2031.
-
5Kitagawa C, Saka H, Kajikawa S, et al. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group(CJLSG) 0601 trial[J]. Cancer Chemother Pharmacol, 2012, 69(5): 1379- 1385.
-
6Kawahara M, Kubo A, Komuta K, et al. A phase I study of amruhicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer:Japan multinational trial organization LC0303[J]. J Thorac Oncol, 2012, 7(12):1845-1849.
-
7Sugiura T, Ariyoshi Y, Negoro S, et al. Phase I / II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer[J]. Invest New Drugs, 2005, 23(4):331-337.
-
8Mitsuoka S, Kudoh S, Kimura T, et al. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer[J]. Osaka City Med J, 2011, 57(2):59-66.
-
9Cui JJ, Tran-Dub6 M, Shen H, et al. Structure based drug design of crizotinib(PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor(c-MET) kinase and anaplastic lymphoma kinase(ALK)[J]. J Med Chem, 2011, 54(18):6342-6363.
-
10Igawa S, Yamamoto N, Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second-and third-line chemotherapy for small cell lung cancer[J]. J Thorac Oncol, 2007, 2(8):741-744.
-
1郭丽丽,唐俊舫,李明智,武玮,陶虹,刘喆.氨柔比星联合顺铂治疗初治广泛期小细胞肺癌患者的临床观察[J].中国医刊,2016,51(8):99-101. 被引量：2
-
2王家美,尚彦君,周启玮.氨柔比星联合顺铂治疗晚期小细胞肺癌患者不良反应的护理[J].护理实践与研究,2012,9(19):83-84. 被引量：1
-
3氨柔比星治疗小细胞肺癌的疗效与人种相关[J].广州医科大学学报,2014,42(6):83-83.
-
4邵岚,张沂平.复发性小细胞肺癌治疗进展[J].国际肿瘤学杂志,2012,39(5):373-376. 被引量：8
-
5王玉艳,刘莉,吴梅娜,仲佳,刘晓红,安同彤,赵军,段建春,王志杰,卓明磊,王洁.氨柔比星治疗小细胞肺癌的疗效分析[J].中华结核和呼吸杂志,2015,38(4):261-266.
-
6伊利替康＋顺铂治疗小细胞肺癌广泛期标准地位暂不可动摇[J].今日药学,2014(4).
-
7肺癌治疗药 氨柔比星amrubicin[J].中国医药技术与市场,2007,7(5):59-60.
-
8氨柔比星在治疗难治性或复发性小细胞肺癌中的作用[J].中华医学信息导报,2007,22(2):11-11.
-
9朱华.肺癌治疗药 氨柔比星(amrubicin)[J].世界临床药物,2004,25(3):187-188. 被引量：3
-
10庄亚琴,姜丽岩.复发性小细胞肺癌的药物治疗现状及展望[J].世界临床药物,2015,36(9):577-583. 被引量：1
